Published in Cancer on December 15, 2007
GI-6207 for Advanced Medullary Thyroid Cancer | NCT01856920
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | NCT02846376
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun (2010) 1.57
Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (2014) 1.35
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
Medical management of malignant melanoma. Aust Prescr (2015) 1.33
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm (2010) 1.22
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med (2015) 1.18
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci (2009) 1.15
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer (2009) 1.09
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07
Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy (2010) 1.04
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol (2011) 0.94
Regulatory T cell: a protection for tumour cells. J Cell Mol Med (2012) 0.91
Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol (2008) 0.90
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89
Cancer vaccines: Looking to the future. Oncoimmunology (2013) 0.88
Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol (2012) 0.87
Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) (2013) 0.87
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis (2014) 0.87
Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) (2016) 0.85
Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des (2011) 0.85
Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy (2009) 0.84
Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol (2013) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells. Cancer Gene Ther (2010) 0.82
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology (2015) 0.82
Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Oncoimmunology (2015) 0.81
Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One (2014) 0.80
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol (2012) 0.80
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget (2015) 0.79
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol (2010) 0.79
Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: a meta-analysis. PLoS One (2013) 0.79
Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79
Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med (2015) 0.78
Predictive factors for immunotherapy in melanoma. Ann Transl Med (2015) 0.77
Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. Sensors (Basel) (2015) 0.76
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse. Clin Dev Immunol (2013) 0.76
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. Front Oncol (2014) 0.76
Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol Cell Pharmacol (2015) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J Radiol (2017) 0.75
Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer (2017) 0.75
Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics (2012) 0.75
[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab. Indian J Nucl Med (2017) 0.75
A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Hum Vaccin Immunother (2017) 0.75
Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. Cureus (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol (2003) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39
Are all hypotheses generated before data analysis prospective? J Clin Oncol (2002) 1.38
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology (2013) 1.16
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother (2012) 1.14
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res (2008) 1.12
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother (2012) 1.11
Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy (2009) 1.10
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 1.09
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A (2006) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res (2008) 1.02
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother (2006) 1.01
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol (2003) 1.00
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology (2012) 0.94
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother (2012) 0.94
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother (2007) 0.91
CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J Immunol (2002) 0.91
Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother (2006) 0.91
Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol (2003) 0.89
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother (2003) 0.89
Mucosal melanoma: pathogenesis, clinical behavior, and management. Curr Oncol Rep (2012) 0.87
Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother (2002) 0.86
Atypical clinical response patterns to ipilimumab. Clin J Oncol Nurs (2011) 0.86
Redirecting T cells. N Engl J Med (2011) 0.85
Integrating new therapies in the treatment of advanced melanoma. Curr Treat Options Oncol (2012) 0.84
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice. Eur J Immunol (2010) 0.84
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med (2014) 0.83
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Am J Clin Oncol (2015) 0.83
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol (2014) 0.83
The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med (2011) 0.82
Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep (2005) 0.81
Allogeneic breast cancer cell vaccines. Clin Breast Cancer (2003) 0.81
Identifying patients at risk for recurrent or advanced BCC. J Drugs Dermatol (2013) 0.81
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Invest New Drugs (2011) 0.81
Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res (2009) 0.80
Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells. Clin Exp Metastasis (2004) 0.78
Altered chemokine receptor sensitivity in FVBN202 rat neu transgenic mice. Breast Cancer Res Treat (2003) 0.78
Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol (2004) 0.78
Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease. J Drugs Dermatol (2013) 0.77
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer (2012) 0.75
Understanding BCC pathogenesis: treatment advancements and challenges. J Drugs Dermatol (2013) 0.75
Selecting patients for KIT inhibition in melanoma. Methods Mol Biol (2014) 0.75
Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes. J Immunother (2003) 0.75
Undefined-antigen vaccines. Cancer Treat Res (2005) 0.75
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. J Immunother (2007) 0.75
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res (2017) 0.75
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother (2017) 0.75
Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma. Dermatol Surg (2012) 0.75